Skip to content

My Pharmacy News

mypharmacynews.com

  • Health News
  • Medications
  • Health Problems
  • Beauty & Balance
  • Personal Health

Home ยป Neurogenic

01/29/2019

Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension

DUBLIN, Jan. 28, 2019 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of

Continue reading »
Latest Posts
Assisted reproductive technology not tied to higher BMI in childhood, finds study
What’s the difference between physical and chemical sunscreens? And which one should you choose?
How medical manufacturing trends are evolving: From performance testing to 3D vision
Health Problems
What are Drug-Induced Nail Disorders?
Current State of Clinical Diagnostics
Machine Learning for Targeted Disease Treatment
Recent Posts
  • Assisted reproductive technology not tied to higher BMI in childhood, finds study
  • What’s the difference between physical and chemical sunscreens? And which one should you choose?
  • How medical manufacturing trends are evolving: From performance testing to 3D vision
  • New tool assesses role of ’embeddedness’ in learning health systems
  • NHS strike chaos begins as A&E unit CLOSES ahead of three-day walk-out
Copyright © 2024
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok